Transcriptomics

Dataset Information

0

Prognostic biomarkers of antipsychotic-induced weight gain


ABSTRACT: Antipsychotic drugs (APs) are used to treat psychiatric disorders but also have the prominent side effect of weight gain resulting in a higher incidence of metabolic disease in this patient group. While the majority of patients gain significant weight in response to APs some patients are relatively resistant to these effects. APs such as clozapine and olanzapine are deemed to be highly efficacious at treating psychiatric conditions yet they have some of the highest weight gain liabilities. Therefore, there is a need to determine which patients are less susceptible to the metabolic side effects of APs and would be good candidates for drugs such as olanzapine, and conversely, identifying patients that should be prescribed alternative APs with less weight gain liabilities.

ORGANISM(S): Mus musculus

PROVIDER: GSE157438 | GEO | 2021/01/01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2013-11-22 | E-GEOD-52615 | biostudies-arrayexpress
2004-09-24 | GSE1501 | GEO
2013-11-22 | GSE52615 | GEO
| PRJEB31532 | ENA
| PRJNA661304 | ENA
2021-04-14 | GSE171977 | GEO
2024-07-03 | GSE268867 | GEO
2021-12-22 | PXD030588 |
2020-06-01 | PXD015049 | Pride
2023-01-13 | GSE221683 | GEO